ArticleMultiple sclerosis and related disorders2021
Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study.
Article in Multiple sclerosis and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis.European journal of medical research · 2024Pooled it
- Neurological manifestations of COVID-19: a retrospective observational study based on 1060 patients with a narrative review.Acta radiologica (Stockholm, Sweden : 1987) · 2023Pooled it
- COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis.Multiple sclerosis and related disorders · 2022Pooled it
- COVID-19 and the risk of CNS demyelinating diseases: A systematic review.Frontiers in neurology · 2022Pooled it
- COVID-19 and Radiological Progression of Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2026Article
- Infection, Relapses, and Pseudo-Relapses in Individuals With Multiple Sclerosis.Neurology. Clinical practice · 2025Article
- Article
- Incidence of multiple sclerosis (MS) relapse after COVID-19 infection: A systematic review and meta-analysis.Caspian journal of internal medicine · 2025Review
- No Genetic Causal Relationship between COVID-19 and Herpes Zoster: A Bidirectional Mendelian Randomization Analysis.Journal of multidisciplinary healthcare · 2025Article
- COVID-19 vaccination in patients with multiple sclerosis: what you need to know - a review.Health science reports · 2024Article
- New-onset or relapse of uveitis after rapid spreading of COVID-19 infection in China and risk factor analysis for relapse.BMC ophthalmology · 2024Article
- COVID-19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark.European journal of neurology · 2024Article
- Protective effect of vaccination on the risk of cardiovascular disease after SARS-CoV-2 infection.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study.Therapeutic advances in neurological disorders · 2024Article
- Vaccination frequency in people newly diagnosed with multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Molecular mimicry and autoimmunity in the time of COVID-19.Journal of autoimmunity · 2023Review
- Review
- Immunopathogenesis of viral infections in neurological autoimmune disease.BMC neurology · 2023Review
- Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study.Multiple sclerosis and related disorders · 2023Observational
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of coronavirus disease (COVID-19) on the risk of relapse in multiple sclerosis (MS) have been unknown. In this retrospective study of 41 relapsing-remitting MS patients, number of relapses in pre-defined at risk-period (ARP) was compared with the previous two years. During the previous two years, a total of 32 attacks was reported, which 5 (15.6%) were during the at-risk period. After adjusting for age and sex, there was an increased risk of attack during ARP compared to the previous two years (RR: 2.566, 95%CI: 1.075-6.124, P=0.034). Our preliminary study suggested that COVID-19 can trigger exacerbation of MS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.